Thomasville National Bank Increases Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Thomasville National Bank increased its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 6.0% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 102,752 shares of the medical equipment provider's stock after acquiring an additional 5,783 shares during the quarter. Thomasville National Bank owned approximately 0.05% of Zimmer Biomet worth $11,629,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also bought and sold shares of ZBH. Stonebridge Financial Group LLC purchased a new stake in Zimmer Biomet in the fourth quarter worth $25,000. Menard Financial Group LLC bought a new position in Zimmer Biomet in the 4th quarter worth $30,000. Accredited Wealth Management LLC purchased a new stake in shares of Zimmer Biomet in the 4th quarter worth about $36,000. Kentucky Trust Co bought a new stake in shares of Zimmer Biomet during the 4th quarter valued at about $39,000. Finally, OFI Invest Asset Management purchased a new position in shares of Zimmer Biomet during the fourth quarter valued at about $40,000. 88.89% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts have commented on the stock. Robert W. Baird lowered their price objective on shares of Zimmer Biomet from $130.00 to $115.00 and set an "outperform" rating for the company in a report on Tuesday, May 6th. The Goldman Sachs Group lowered their target price on Zimmer Biomet from $120.00 to $104.00 and set a "neutral" rating for the company in a research note on Tuesday, May 6th. Canaccord Genuity Group dropped their price target on Zimmer Biomet from $115.00 to $101.00 and set a "hold" rating on the stock in a research report on Monday, May 12th. BTIG Research reaffirmed a "buy" rating on shares of Zimmer Biomet in a research note on Monday, April 14th. Finally, Stifel Nicolaus set a $115.00 price objective on Zimmer Biomet and gave the company a "buy" rating in a research report on Tuesday, May 6th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eight have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $111.53.

Zimmer Biomet Trading Down 2.2%

ZBH stock traded down $2.03 during midday trading on Friday, reaching $91.23. 1,370,283 shares of the company traded hands, compared to its average volume of 1,790,451. The firm has a market capitalization of $18.05 billion, a price-to-earnings ratio of 20.50, a P/E/G ratio of 1.95 and a beta of 0.72. Zimmer Biomet Holdings, Inc. has a 52-week low of $89.22 and a 52-week high of $116.71. The business has a 50 day moving average of $96.71 and a 200-day moving average of $103.70. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The medical equipment provider reported $1.81 EPS for the quarter, beating the consensus estimate of $1.77 by $0.04. The company had revenue of $1.91 billion for the quarter, compared to the consensus estimate of $1.89 billion. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. Zimmer Biomet's quarterly revenue was up 1.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.94 EPS. As a group, sell-side analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Thursday, June 26th will be paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 1.05%. The ex-dividend date is Thursday, June 26th. Zimmer Biomet's dividend payout ratio (DPR) is presently 21.24%.

Insiders Place Their Bets

In other Zimmer Biomet news, insider Sang Yi sold 1,000 shares of the firm's stock in a transaction that occurred on Wednesday, June 11th. The shares were sold at an average price of $95.00, for a total transaction of $95,000.00. Following the completion of the transaction, the insider now directly owns 20,424 shares of the company's stock, valued at approximately $1,940,280. This trade represents a 4.67% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 1.39% of the stock is owned by insiders.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.